// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Bacteremia in Kidney Transplant Recipients: Incidence, Risk Factors, and Outcomes.

S. Brar - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Outcomes of FOLFIRINOX (FFX) and gemcitabine+nab-paclitaxel (GnP) in initially unresectable locally advanced pancreatic cancer (uLAPC): A population-based study.

Kelvin K. Chan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Health-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trial.

Simron Singh - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation.

D. Kumar - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Mycophenolic acid

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.

Shaan Dudani - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Beta Cell-Specific Free Circulating DNA May Predict the Outcome After Clinical Islet Transplantation.

B. Gala-Lopez - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).

Johanna C. Bendell - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bevacizumab

Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis.

Daniel Adam Breadner - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Capecitabine

Interim results of a multicenter phase ll trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).

Jill Lacy - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Multivariate assessment of SPARC expression in resected pancreatic ductal adenocarcinoma to identify subgroups that are sensitive to adjuvant gemcitabine.

Steve Kalloger - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Can Viral Load Be Used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Metaanalysis.

Y. Natori - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

N/A

Application of the ASCO framework for assessing value in metastatic colorectal cancer clinical trials.

Doreen Anuli Ezeife - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

CD16a-Activated NK Cells in ABMR Are Highly Similar to CD3-Activated Effector T Cells in TCMR.

M. Parkes - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Other

N/A

N/A

CD4 and CD8 T Cells: Respectively Reprogrammed and Recapitulated in the Neonate to Induce Transplant Tolerance.

R. Bascom - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CD4 T Cells and Co-Engagement with Foreign Protein Are Required in Antibody Response to Non-Self Blood Group A-Antigen.

I. Adam - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Challenges for the Travelling Donor: Variability Between Donor Work-Up and Donor Surgery in the Canadian Kidney Paired Donation Program.

B. Reikie - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cost-effectiveness of surveillance after curative resection (CR) of metastatic colorectal cancer (CRC).

Richard M. Lee-Ying - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Clearance of Transaminases During Normothermic Ex Vivo Liver Perfusion.

M. Bral - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

N/A

Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).

Hui-Li Wong - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Clinical Correlation of Endomyocardial Biopsies Molecular Profiling: Taking Rejection Diagnosis Beyond Histology.

L. Potena - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Other

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved